MMP-2/MMP-9 Fluorogenic Substrate I|cas 135662-07-6

Cas No.:	135662-07-6
Synonyms:	Dnp-PLGMWSR；Dnp-Pro-Leu-Gly-Met-Trp-Ser-Arg-OH；Matrix Metalloproteinase-2/Matrix Metalloproteinase-9 Fluorogenic Substrate I；MMP-2/MMP-9 Fluorogenic Substrate I
SMILES:	O=C(N[C@@H](CO)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)[C@@H](NC([C@H](CCSC)NC(CNC([C@H](CC(C)C)NC([C@H]1N(C2=CC=C([N+]([O-])=O)C=C2[N+]([O-])=O)CCC1)=O)=O)=O)=O)CC3=CNC4=C3C=CC=C4
Formula:	C₄₄H₆₁N₁₃O₁₃S
M.Wt:	1012.1
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Dnp-PLGMWSR is a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-9.The activity of MMP-2 and MMP-9 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitrophenol (Dnp) group.

Cat. No.	Product name	Field of application
DC47568	ADAM8-IN-1	ADAM8-IN-1 is a potent ADAM8 inhibitor with an IC50 value of 73 nM.
DC46499	CP-544439	CP-544439 is a potent and orally active matrix metalloproteinase-13 (MMP-13) inhibitor with an IC50 of 0.75 nM.
DC46250	FFAGLDD TFA	FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release.
DC46249	FFAGLDD	FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release.
DC41852	CTTHWGFTLC, CYCLIC TFA	CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM.
DC29148	GPLGIAGQ TFA	GPLGIAGQ TFA, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ TFA can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT).
DC29147	GPLGIAGQ	GPLGIAGQ, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT).
DC28327	PF-00356231 hydrochloride	PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase MMP-12 (IC50=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC50s of 0.00065, 1.7, 0.98, 0.39 μM, respectively.
DC28288	XL-784 free base	XL-784 free base is a selective matrix metalloproteinases (MMP) inhibitor, with IC50s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1，MMP-2，MMP-3，MMP-8，MMP-9，MMP-13，respectively.
DC28205	UK-370106	UK-370106 is a potent and highly selective MMP-3 (IC50 of 23 nM) and MMP-12 (IC50 of 42 nM) inhibitor with >1200-fold higher potency than MMP-1, MMP-2, MMP-9, and MMP-14, and about 100-fold than MMP-13 and MMP-8. UK-370106 potently inhibits cleavage of [3H]-fibronectin by MMP-3 (IC50 of 320 nM) and has little effect on keratinocyte migration in vitro.